Consumers

Personal importation
For travellers
Buying online

Health Professionals

Reporting problems
Unapproved products
Special access scheme

Industry

SME Assist
Regulation basics
Scheduling basics

Recalls and suspensions

Subscribe to TGA safety information

Palexia SR 100 mg tapentadol sustained release tablets

14 February 2020
Product defect correction - potential for blank labelling to pose risk of accidental misuse

Brauer Teething Gel 20 g

29 November 2019
Recall - bacterial contamination of one batch

Accu-Chek Guide and Accu-Chek Performa blood glucose meters

14 November 2019
Product defect correction – risk of delayed therapy due to potential battery issues

Jin Gui Shen Qi Wan (oral pills)

5 September 2019
Recall - potential toxicity (金 匮 肾 气 丸 - statement includes Chinese translation 中文翻译)

More safety information »

Safety information

Subscribe to TGA safety information

No evidence to support intravenous high-dose vitamin C in the management of COVID-19

27 March 2020
We have investigated a report that intravenous high-dose vitamin C may be beneficial in the management of COVID-19

New restrictions on prescribing hydroxychloroquine for COVID-19

24 March 2020
Only certain types of specialists will be able to prescribe hydroxychloroquine to new patients

No evidence to support claims ibuprofen worsens COVID-19 symptoms

20 March 2020
TGA monitoring

2020 seasonal influenza vaccines

13 March 2020
Information for consumers and health professionals

More safety information »

News

Subscribe to TGA latest news and updates

COVID-19 test kits included on the ARTG for legal supply in Australia

31 March 2020
A list of tests approved for inclusion on the Australian Register of Therapeutic Goods (ARTG).

Expedited COVID-19 medical device application process

31 March 2020
All applications in relation to COVID-19 are being expedited as a matter of priority (separate to the Priority Review pathway)

Clinical trial processes

31 March 2020
Information relating to COVID-19

AusPAR: Nivolumab

31 March 2020
Australian Public Assessment Report for Nivolumab

More news »

Latest tweets

Connect